Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Rhea-AI Summary
Anixa Biosciences (NASDAQ: ANIX) announced that Chairman and CEO Dr. Amit Kumar will be interviewed on the RedChip Small Stocks, Big Money™ show airing on Bloomberg TV Saturday, May 2, 2026 at 7pm ET. The interview will review the company, its capital‑efficient model, the breast cancer vaccine Phase 1 results showing protocol‑defined immune responses in 74% of participants, and ongoing positive survival data for ovarian CAR‑T therapy lira‑cel in a Phase 1 trial. Bloomberg TV reaches an estimated 73 million U.S. homes; the segment is also available online via Anixa’s website.
Positive
- None.
Negative
- None.
News Market Reaction – ANIX
In the May 1 session, ANIX gained 4.67%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Patent issuance | Positive | -4.3% | Mexican patent No. 432748 issued, extending breast cancer vaccine IP into 2040s. |
| Apr 22 | Conference presentation | Positive | +2.6% | ISCT 2026 meeting presentation on Phase 1 ovarian cancer CAR-T therapy lira-cel. |
| Apr 09 | Investor conference | Positive | +0.4% | RedChip virtual conference talk on breast cancer vaccine and ovarian CAR-T data. |
| Apr 07 | Investor conference | Positive | +3.9% | Water Tower Research conference presentation covering strategy and key clinical updates. |
| Apr 06 | Media interview | Positive | +1.6% | Smart Money Circle interview on advancing cancer immunotherapy pipeline and trial progress. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company-focused news, especially on clinical progress and investor outreach, has typically led to modest positive moves, with one divergence where patent news coincided with a decline.
Over the past month, Anixa has repeatedly highlighted two main programs: its Phase 1 breast cancer vaccine that met primary endpoints with protocol-defined immune responses in 74% of participants, and its ovarian cancer CAR-T therapy lira-cel showing positive survival data in an ongoing Phase 1 trial. Updates have come via conferences, CEO interviews, and a Mexican patent (Patent No. 432748) extending IP into the 2040s. Most of these communications saw modest positive price reactions, framing today’s TV interview as part of an ongoing visibility and outreach effort.
Key Terms
car-t therapy medical
phase 1 clinical trial medical
breast cancer vaccine medical
immune responses medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
During the interview, Dr. Kumar will provide an overview of the Company and its capital efficient business model, as well as the Company's breast cancer vaccine meeting primary endpoints and generating protocol-defined immune responses in
You may view the segment on Bloomberg TV (for channel information, check your local listings) or on the internet at Anixa Biosciences (ANIX): CEO on Breast Cancer Vaccine, Phase 2 Catalyst & Ovarian Cancer CAR-T Data.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-interview-to-air-on-the-redchip-small-stocks-big-money-show-on-bloomberg-tv-302759814.html
SOURCE Anixa Biosciences, Inc.